KaloCyte

St. Louis, United States Founded: 2016 • Age: 10 yrs
Nanotechnology-based red blood cell substitutes are developed.
Request Access

About KaloCyte

KaloCyte is a company based in St. Louis (United States) founded in 2016 by Dipanjan Pan, Philip Spinella, and Allan Doctor.. KaloCyte has raised $1.1 million across 6 funding rounds from investors including HHS, NYBC Ventures and Maryland Momentum Fund. KaloCyte offers products and services including ErythroMer. KaloCyte operates in a competitive market with competitors including Satellite Bio, CorNeat Vision, Stratatech Corp, Morphocell Technologies and Haimai Medical, among others.

  • Headquarter St. Louis, United States
  • Founders Dipanjan Pan, Philip Spinella, Allan Doctor
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Kalocyte, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $1.1 M (USD)

    in 6 rounds

  • Latest Funding Round
    $2.46 M (USD), Grant

    Apr 15, 2024

  • Investors
    HHS

    & 2 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of KaloCyte

KaloCyte offers a comprehensive portfolio of products and services, including ErythroMer. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Dried substitute for red blood cells in trauma and emergencies.

People of KaloCyte
Headcount 10-50
Employee Profiles 4
Employee Profiles
People
Elaine Haynes
President and CEO, Board Director
People
George Allen Hides
Vice President, Regulatory Affairs and Operations
People
Tom Krenning
Project Manager, Agile Coach, and Regulatory Writing Consultant

Unlock access to complete

Funding Insights of KaloCyte

KaloCyte has successfully raised a total of $1.1M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $2.46 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 6
  • Last Round Grant — $2.5M
  • First Round

    (11 May 2017)

  • Investors Count 3
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2024 Amount Grant - KaloCyte Valuation

investors

HHS
Jul, 2022 Amount Seed - KaloCyte Valuation

investors

Jun, 2020 Amount Seed - KaloCyte Valuation Maryland Momentum Fund
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in KaloCyte

KaloCyte has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, NYBC Ventures and Maryland Momentum Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Investment funding is provided for University System of Maryland ventures.
Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by KaloCyte

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - KaloCyte

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Kalocyte Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of KaloCyte

KaloCyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Satellite Bio, CorNeat Vision, Stratatech Corp, Morphocell Technologies and Haimai Medical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Proprietary implantable satellite organs are developed for cell therapy.
domain founded_year HQ Location
Nanotechnology-based artificial corneal implants are developed for ophthalmic use.
domain founded_year HQ Location
Cell-based skin substitutes are developed for therapeutic and research uses.
domain founded_year HQ Location
Engineered liver tissues are developed for liver disease treatments.
domain founded_year HQ Location
Tissue engineering technologies for cardiovascular regenerative surgeries are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Kalocyte

Frequently Asked Questions about KaloCyte

When was KaloCyte founded?

KaloCyte was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is KaloCyte located?

KaloCyte is headquartered in St. Louis, United States. It is registered at St. Louis, Missouri, United States.

Is KaloCyte a funded company?

KaloCyte is a funded company, having raised a total of $1.1M across 6 funding rounds to date. The company's 1st funding round was a Seed of $300K, raised on May 11, 2017.

What does KaloCyte do?

KaloCyte was founded in 2016 in St. Louis, United States, within the biotechnology sector. A nanotechnology platform is utilized to create ErythroMer, an immuno-silent nanoparticle designed to mimic red blood cell surfaces and facilitate oxygen binding and gas exchange. The technology is directed toward trauma care in low-resource environments, such as battlefields and remote areas, to address blood loss mortality. Operations focus on advancing this substitute for clinical applications.

Who are the top competitors of KaloCyte?

KaloCyte's top competitors include Satellite Bio, Stratatech Corp and Morphocell Technologies.

What products or services does KaloCyte offer?

KaloCyte offers ErythroMer.

Who are KaloCyte's investors?

KaloCyte has 3 investors. Key investors include HHS, NYBC Ventures, and Maryland Momentum Fund.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available